Robust approaches for chemogenetic control of protein function would have many biological applications. We developed stabilizable polypeptide linkages (StaPLs) based on hepatitis C virus protease. StaPLs undergo autoproteolysis to cleave proteins by default, whereas protease inhibitors prevent cleavage and preserve protein function. We created StaPLs responsive to different clinically approved drugs to bidirectionally control transcription with zinc-finger-based effectors, and used StaPLs to create single-chain, drug-stabilizable variants of CRISPR-Cas9 and caspase-9.
As the ability to control two processes in the same cell independently would be desirable, we first created two NS3 protease variants inhibited by different drugs, asunaprevir (ASV) and telaprevir (TPV), thereby diverging NS3 into two species defined by drug sensitivity (Supplementary Note 1, Supplementary Table 1 , and Supplementary Fig. 1 ). These two variants, denoted by NS3 AI (ASV inhibited) and NS3 TI (TPV inhibited), were orthogonal in their drug sensitivity, with NS3 AI being highly resistant to 1-10 μ M TPV and NS3 TI being highly resistant to 0.1-1 µ M ASV ( Supplementary  Fig. 2a -c). SMASh tags containing NS3 AI or NS3 TI ( Supplementary  Fig. 2d ) allowed ASV or TPV, respectively, to suppress accumulation of fused YFP (Fig. 1b ). Together, they allowed for simultaneous independent suppression of two protein targets ( Fig. 1c ), which shows that NS3 AI -ASV and NS3 TI -TPV are indeed orthogonal protease-inhibitor pairs. We next explored the possibility of regulating the linkage of other functional domains in a synthetic fusion protein. We linked an NS3 protease cleavage site to either NS3 AI or NS3 TI , and referred to these sequences as StaPL modules ( Supplementary Fig. 3a ). We then used StaPL AI and StaPL TI modules to connect a nuclear localization sequence (NLS) to either tandem dimeric YFP (tdYFP) or tandem dimeric RFP (tdRFP). Preservation of each StaPL linkage occurred only with the cognate inhibitor ( Supplementary Fig. 3b ), and nuclear localization of tdYFP and tdRFP could be controlled independently in the same cells ( Supplementary Fig. 4 ). Thus, orthogonal StaPL-drug pairs allow independent regulation of two proteins.
We next used StaPL sequences to bidirectionally control gene expression. We chose to regulate vascular endothelial growth factor (VEGF), as VEGF upregulation can be beneficial in neuropathy or vascular insufficiency 11 , whereas its downregulation can be useful for wet age-related macular degeneration and cancer 12 . We first expressed in HEK293A cells a synthetic zinc-finger domain targeting the VEGFA promoter 13 (ZF VEGFA ) fused either to StaPL AI followed by tdYFP and a p65 activation domain, or to StaPL TI followed by tdRFP and a KRAB repressor domain, while also testing two substrate sequences in the StaPL modules. As expected, full-length proteins were preserved only in the presence of the cognate drug ( Supplementary Fig. 5a ). We then tested whether these constructs could mediate pharmacological regulation of endogenous VEGFA by quantifying VEGF secreted from transfected cells ( Supplementary  Fig. 5b ). Although TPV stabilization of the KRAB-based repressor downregulated VEGF as desired, ASV stabilization of the p65based activator had unclear effects. We therefore replaced p65 with the more potent VP64-p65-Rta (VPR) cassette 14 and reconfirmed drug-dependent protein preservation using the more efficiently cleaved DEMEEC/S substrate ( Supplementary Fig. 5a,c ). Finally, we tested the ability of the two final constructs, ZF VEGFA -StaPL TI -tdRFP-KRAB and ZF VEGFA -StaPL AI -YFP-VPR ( Supplementary  Fig. 6 ), to regulate VEGFA transcription ( Fig. 1d ). Individually, ZF VEGFA -StaPL TI -tdRFP-KRAB decreased VEGF secretion specifically in TPV, whereas ZF VEGFA -StaPL AI -YFP-VPR strongly increased VEGF secretion specifically in ASV. In cells coexpressing both constructs, VEGF was upregulated by ASV and downregulated by TPV, demonstrating orthogonal regulation (Fig. 1d ). Thus, StaPL modules can regulate linkage between DNA-binding and regulatory domains in synthetic transcription factors, with two orthogonal StaPL-drug pairs enabling bidirectional control of an endogenous gene.
We then investigated whether StaPL modules in internal loops can regulate protein function. We inserted StaPL TI into nucleasedeficient Streptococcus pyogenes Cas9 (dSpCas9) with an N-terminal fusion to VPR (VPR-dCas9), choosing positions 573 and 1,246, in nonconserved loops of dSpCas9. To assay for function, we transfected these constructs and a single guide RNA (sgRNA) targeting a tet operator (tetO) sequence into HEK293 cells stably expressing mCherry from a TRE3G promoter containing seven tetO repeats 15 . We expected the dSpCas9 domain to be cleaved into nonfunctional fragments by default, but also to retain its ability to fold and function in TPV ( Fig. 2a ). Both constructs activated RFP expression in TPV, with the variant at 1,246 performing better ( Supplementary  Fig. 7a,b ). Cells expressing this protein, VPR-dSpCas9(StaPL TI ) ( Supplementary Fig. 8 ), increased RFP fluorescence 24-fold and RFP mRNA expression 6-fold after 24 h in TPV compared with vehicle ( Fig. 2b,c) . Thus, intradomain insertion of a StaPL module enables pharmacological regulation of VPR-dSpCas9 function.
Next, we characterized the kinetics, reversibility, and dose responsiveness of transcriptional activation by StaPL (Supplementary Note 2). Kinetics were consistent with the accumulation of new intact protein copies in the presence of drug ( Supplementary Fig. 9a -c). Reversal was not observed 24 h after the removal of TPV from VPR-dSpCas9(StaPL TI ), but was observed after the removal of ASV from ZF VEGFA -StaPL AI -YFP-VPR, consistent with the known covalent mechanism of action of TPV and noncovalent mechanism of action of ASV ( Supplementary  Fig. 9d ,e). The dose responsiveness of VPR-dSpCas9(StaPL TI ) and ZF VEGFA -StaPL AI -YFP-VPR mirrored that of SMASh TI and SMASh AI , respectively ( Supplementary Fig. 9f ,g and Supplementary Tables 2  and 3) , indicating consistent drug responsiveness of the NS3 TI and NS3 AI proteases in different contexts.
Finally, we postulated that StaPL sequences could enable drugdependent preservation of a tandem dimer. This would allow proteins naturally activated by homodimerization to be activated by NS3 protease inhibitors. We tested this concept on caspase-9 (Casp9), whose natural activation involves dimerization of an N-terminal domain and which can be artificially activated by chemically induced dimerization 16 . We created a fusion protein consisting of, in order, a minimal Casp9 protease domain, a StaPL AI module, and a second copy of the Casp9 protease domain ( Fig. 2d and Supplementary Fig. 10 ). Stabilization of this tandem dimer, referred to as StaPL-dimerized Casp9 (StaPLd-Casp9), would be expected to cause Casp9 autoactivation and subsequent apoptosis in ASV ( Fig. 2d ). For testing, we also created a catalytically inactive variant, StaPLd-Casp9 C287S . We then expressed these constructs from the same locus in HeLa cells by means of targeted recombination, with a downstream IRES-RFP cassette as an expression marker. As expected, cells stably expressing StaPLd-Casp9 C287S produced cleaved Casp9 monomer bands in the absence of ASV, but produced full-length protein after 24 h of ASV treatment ( Supplementary Fig. 11a ). For cells expressing the catalytically active StaPLd-Casp9, we also observed Casp9 monomer bands in the absence of ASV, but we did not detect Casp9, RFP, or the ubiquitous protein β -actin in ASV-treated cells by immunoblotting, which suggests cell loss before lysate preparation ( Supplementary Fig. 11a ). ASV-induced cell death was confirmed by brightfield imaging ( Supplementary Fig. 11b ), and apoptosis was confirmed by annexin staining and flow cytometry ( Supplementary  Fig. 11c,d) . A fluorescent indicator for the downstream caspase-3 confirmed that StaPLd-Casp9 triggered apoptosis via activation of the caspase cascade ( Fig. 2e,f ). As expected, the dose responsiveness of apoptosis to ASV reflected that of NS3 AI inhibition, with maximal apoptosis at 1 μ M ( Supplementary Fig. 12a,b ). Thus, regulation of Casp9 dimerization by StaPL enables an NS3 protease inhibitor to trigger cell death.
StaPLd-Casp9 is similar to iCasp9, a Casp9 fusion protein that is activated by dimerizing rapalogs such as AP20187 and that is being tested as a safety switch for cellular therapies such as chimeric antigen receptor T cells 16, 17 . StaPLd-Casp9 could have similar applications as iCasp9, while using a clinically approved drug. We confirmed that StaPLd-Casp9 and iCasp9 were activated specifically by their respective drugs to induce comparable maximum levels of apoptosis after 24 h ( Supplementary Fig. 13 ). The orthogonality of the two systems suggests that they could be used to control two populations of cells independently in vivo. Given that intact copies of StaPLd-Casp9 would need to accumulate in ASV to induce apoptosis, whereas preexisting copies of iCasp9 should induce apoptosis once a certain concentration of AP20187 is reached, the time course of apoptosis with StaPLd-Casp9 should be more gradual than that with iCasp9. Indeed, apoptosis was more gradual with ASV and StaPLd-Casp9 than with AP20187 and iCasp9 (time to maximum effect of 24 h versus 3 h; Supplementary Fig. 14a,b ). This suggests that a StaPLd-Casp9-expressing cell population could be partially depleted by intermittent dosing of ASV, which could be useful for rheostatic control of cellular therapies. In summary, we describe a generalizable design for drug-inducible proteins in which proteins are rescued from StaPL-induced fragmentation by HCV NS3 protease inhibitors. As examples, we used StaPL modules to confer drug control on protein localization and on the functional output of zinc-finger-based transcriptional regulators. We also demonstrated that internal insertion of a StaPL module can be used to regulate a CRISPR-Cas9-based transcriptional activator, and to regulate apoptosis through linkages of two copies of Casp9 with a StaPL module. Potential advantages of StaPL over existing techniques for drug control of protein function include simplicity, robustness, multiplexibility, and the use of clinically approved drugs (Supplementary Note 3). We expect that StaPL modules can be used to create drug-stabilized forms of many other natural proteins. For example, loop insertion of StaPL modules could create drug-inducible forms of Cas9 proteins from various species. This will allow targeting of two different genes by two different sgRNAs and regulation by two different drugs while involving the expression of only two polypeptide chains (for example, SpCas9 with a StaPL AI insert and Staphylococcus aureus Cas9 with a StaPL TI insert), compared with four polypeptides when heterodimerizing systems are used 18, 19 . More generally, many proteins tolerate the insertion of protein domains into exposed loops 20 , and should therefore be amenable to drug regulation via internal StaPL module insertion and linkage preservation by NS3 protease inhibitors.
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Methods

DNA plasmids and molecular cloning.
Plasmids were constructed via standard molecular biology techniques: restriction enzyme digest (Fermentas), PCR and overlap extension PCR with PrimeSTAR polymerase (Clontech), and assembly using either In-Fusion enzyme (Clontech) or T4 ligase (Thermo Fisher). DNA was transformed into XL10 Gold (Agilent) or Stellar (Clontech) competent Escherichia coli cells with ampicillin (100 µ g/ml) selection. Plasmid DNA was isolated with the PureLink hiPure Plasmid Maxiprep kit (Thermo Fisher) or the Plasmid Plus Midiprep kit (Qiagen). Subcloned regions were verified by Sanger sequencing, assisted by Geneious software (Biomatters).
Hepatitis C virus sequences used in this study were derived from genotype 1a HCV (GenBank accession number NC_004102). Plasmids encoding PSD95-SMASh, Arc-SMASh, and (Venus) YFP-SMASh mutant variants were under the control of the CMV promoter in the pCMV-SPORT6 backbone (Life Technologies), and were adapted from those described previously 10 Zinc-finger (ZF) plasmids, in the pCMV-SPORT6 backbone, consisted of a ZF DNA-binding domain and hemagglutinin (HA) epitope tag, connected to a StaPL module via a DEMEEC/S or EDVVCC/H cleavage site, followed by a fluorescent protein marker (YFP, tdYFP, or tdRFP), a transcriptional effector (p65, VPR, or KRAB), and a tandem SV40 NLS attached via a DEMEEC/S cleavage site. The human SP1 protein-derived ZF domain architecture targeted a 10-bp region (GGGGAGGATC) beginning 8 nt upstream of the transcriptional start site (TSS) of the human VEGFA locus, and was described previously 13 . The KRAB repressor consisted of the first 97 residues of the human KOX1 protein. The p65 activator consisted of the last 101 residues of the human NF-κ B protein. ZF, p65, and KRAB were synthesized de novo by assembly PCR from oligonucleotides, assisted by the DNAWorks algorithm. VPR activator (VP64-p65-Rta) was amplified from a VPR-dSaCas9 plasmid (a gift from the L.S. Qi lab, Stanford University) and its internal NLS was replaced with a GGSGGS linker.
The S. pyogenes Cas9 constructs, which carried nuclease-deactivating mutations D10A and H840A (dSpCas9), were under the control of the PGK promoter and consisted of a VPR transcriptional activator domain linked to BFP, dSpCas9 (with or without a DEMEEC/S cleavage site and StaPL TI module inserted into an internal loop), and a tandem NLS. In these constructs, the VPR's internal NLS was replaced with a GGSGGSGGS linker. These constructs were adapted from a PGK-VPR-BFP-dSpCas9 plasmid, which was a gift from the L.S. Qi lab, as was a U6-sgRNA/CMV-GFP plasmid that expressed an S. pyogenes sgRNA directed to the TRE3G locus (target sequence GTACGTTCTCTATCACTGATA on nontemplate strand).
Human Casp9 (excluding its CARD caspase recruitment domain) was amplified from the pET23b-Casp9-His plasmid (a gift from the G. Salvesen lab; Addgene plasmid # 11829) 21 . Dual copies of the Casp9 large and small subunits were linked together by an HA epitope tag, a DEMEEC/S cleavage site, and a StaPL AI module. This StaPLd-Casp9 construct was subcloned into the pcDNA5/ FRT shuttle vector (Thermo Fisher), which contains a CMV promoter. An internal ribosome entry sequence (IRES) and a coding sequence for eqRFP (a monomeric RFP from Entacmaea quadricolor) were placed downstream of StaPLd-Casp9. The iCasp9 gene was amplified from the pMSCV-Fdel Casp9.IRES.GFP plasmid (a gift from the D. Spencer lab; Addgene plasmid # 15567) 16 and subcloned into the IRES:eqRFP-containing pcDNA5/FRT shuttle vector. We also made catalytic dead variants of StaPLd-Casp9 and iCasp9 by introducing a C287S mutation into each of the large subunits.
Molecular modeling. Manipulation of protein crystal structures was done with UCSF Chimera 22 and MacPyMol (Schrödinger). Cocrystals of the HCV NS4A/NS3 protease in complex with asunaprevir (PDB 4WF8) 23 or telaprevir (PDB 3SV6) 24 were modified to include the relevant mutations, and (if applicable) the inhibitor molecule was removed. Structures were then energy-minimized in Chimera and reimported into MacPyMol for image generation. dSpCas9 was modeled with a cocrystal of Cas9 and sgRNA (PDB 4ZT0) 25 .
Cell culture and transfection. HEK293A (Life Technologies) and HeLa (ATCC) cells were passaged in 100-mm dishes (Falcon) and cultured at 37 °C in 5% CO 2 in high-glucose DMEM (Hyclone or Life Technologies) supplemented with 10% (v/v) FBS (Gemini) or 10% calf serum (Gemini), 2 mM glutamine (Gemini), 100 U/ml penicillin, and 100 µ g/ml streptomycin (Gemini). Cell cultures were not tested for mycoplasma. For dSpCas9 experiments, monoclonal stable HEK293 cells with a TRE3G-mCherry cassette were used (gift from the L.S. Qi lab) and cultured similarly. For HEK293A and HeLa cells, transfections were performed with Lipofectamine 2000 or Lipofectamine 3000 (Life Technologies) and Opti-MEM (Life Technologies) according to the manufacturer's instructions. For the HEK293-TRE3G-mCherry cell line, either the CalPhos mammalian transfection kit (Clontech) or Lipofectamine 2000 was used. For CalPhos-transfected cells, media was aspirated and replaced with fresh drug-containing media 24 h after transfection. Negative control transfections were carried out with the pCMV-SPORT6 plasmid. For cotransfections with dSpCas9 variants and sgRNA, DNA amounts were adjusted to produce a 1:1 molar ratio of dSpCas9 plasmid to sgRNA plasmid.
Monoclonal stable HeLa lines expressing StaPLd-Casp9 and iCasp9 constructs were generated via the Flp-In system (Life Technologies). Flp-In T-REx HeLa cells (gift from S. Taylor lab, University of Manchester) 26 were initially maintained in DMEM supplemented as described above, and also with 100 µ g/ml Zeocin (Thermo Fisher). Lipofectamine 2000 transfections were done in 100-mm dishes in Zeocin-free media. For generation of the C287S StaPLd-Casp9 and iCasp9 variant cell lines, cells were cotransfected with the appropriate pcDNA5/FRT shuttle vector and the FLP recombinase expression vector pOG44 (10% shuttle vector, 90% pOG44, by mass). For the wild-type StaPLd-Casp9 and iCasp9 cell lines, cells were also cotransfected with the pcDNA3-XIAP-Myc plasmid (a gift from the G. Salvesen lab; Addgene plasmid # 11833; 10% shuttle vector, 20% pcDNA3-XIAP-Myc, 70% pOG44, by mass). Coexpression of the antiapoptotic protein XIAP was performed to prevent any premature apoptosis due to overexpression of StaPLd-Casp9 or iCasp9. After 48 h, cells were trypsinized with 0.25% trypsin EDTA solution (Gemini) and replated in 12-well plates (Greiner Bio-One) in DMEM containing 200 µ g/ml hygromycin B (Life Technologies) for selection. Colonies were picked, trypsinized, expanded, and verified by vulnerability to zeomycin, eqRFP fluorescence, HA immunopositivity by western blotting, and extraction of genomic DNA (DNeasy blood and tissue kit; Qiagen) for PCR amplification and sequencing confirmation of the inserted Casp9 suicide gene. Downstream experiments were performed in hygromycin-B-containing DMEM.
Chemical reagents. TPV and staurosporine (STS) were obtained from AdooQ Biosciences, and ASV was obtained by custom synthesis (Acme Bioscience). ASV is also commercially available as a research reagent. AP20187 (AP) was purchased from ApexBio. Stocks of each compound were made at 1,000× the final concentration in dimethysulfoxide (DMSO; Santa Cruz Biotechnology) and stored at -20 °C. For experiments with transfected plasmids, ASV and TPV were applied to cells directly before transfection or along with transfection reagents, unless otherwise indicated. Cobalt(II) chloride hexahydrate (CoCl 2 ; Sigma Aldrich) was dissolved in water to make a 400 mM (500× ) stock. In applicable experiments, cells were incubated in 800 µ M CoCl 2 for the final 7 h before harvest to simulate hypoxia.
Antibodies. The following primary antibodies were used for immunoblotting at the indicated dilutions: mouse monoclonal anti-PSD95 (NeuroMab; clone K28/43), 1:1,000; rabbit polyclonal anti-β -actin (GeneTex; GTX124214), 1:3,333; rabbit polyclonal anti-GAPDH (Santa Cruz; FL-335/sc-25778), 1:500; rabbit polyclonal anti-Arc (Synaptic Systems; 156 003), 1:200; mouse monoclonal anti-GFP (Pierce; clone GF28R/MA5-15256), 1:1,000; rabbit polyclonal anti-tdTomato (OriGene; TA150128), 1:2,000; rabbit monoclonal anti-HA (Cell Signaling; C29F4), 1:1,000; mouse monoclonal anti-GAPDH (Santa Cruz; clone G-9/sc-365062), 1:500; mouse monoclonal anti-HA (Santa Cruz; clone F-7/sc-7392), 1:1,000; rabbit polyclonal anti-eqRFP (Evrogen; AB233), 1:1,000; mouse monoclonal anti-β -actin (Santa Cruz; ACTBD11B7/sc-81178), 1:1,000. Secondary antibodies were either LI-COR 680RD goat-anti-mouse and 800CW goat-anti-rabbit, or 680RD goat-anti-rabbit and 800CW goat-anti-mouse. Secondaries were used at 1:3,333.
Immunoblotting. For SDS-PAGE analysis, cells were cultured in 24-or 12-well plates (Greiner Bio-One) for 8-48 h after transfection and drug addition. Culture media were removed, and then cells were lysed with 50 or 100 µ l of hot (90 °C) SDS lysis buffer (100 mM Tris-HCl, pH 8.0, 3% SDS, 20% glycerol, 0.2% bromophenol blue, 10% 2-mercaptoethanol). Lysates were sonicated to shear DNA, heated briefly to 90 °C, centrifuged, and loaded on either NuPAGE 4-12% Bis-Tris (Life Technologies) or 4-15% Criterion TGX (Bio-Rad) gels, along with Novex Sharp pre-stained protein standard (Life Technologies). Transfers onto PVDF membrane were performed using either the iBlot system (Life Technologies) or the Trans-Blot Turbo system (Bio-Rad).
Membranes were typically probed with primary and secondary antibodies using the iBind system (Life Technologies). Alternatively, we carried out immunoprobing by blocking the membrane with 7.5% (w/v) nonfat dry milk in Tris-buffered saline (TBS) for 1 h at ambient temperature on an electric rocker, washing it three times with TBS with 0.1% Tween 20 (TBS-T), incubating it for 1 h with primary antibodies in 5% BSA in TBS-T, washing it three times in TBS-T, incubating it for 1 h with fluorescent secondary antibodies in 7.5% nonfat dry milk in TBS-T, and washing it a final three times in TBS-T.
For the immunoblotting experiment depicted in Supplementary Fig. 1b , membranes were cut into two sections and truncated in order to stain all PSD95 sections in parallel with mouse anti-PSD95, and all GAPDH sections in parallel with rabbit anti-GAPDH. In all other cases, membranes were stained intact. Immunoblotting membranes were scanned with an Odyssey or CLx imager (LI-COR). Membrane scans were cropped to generate figures. Uncropped versions of non-truncated immunoblotting membranes are available ( Supplementary Fig. 15 ).
Western blotting quantifications were done in the Fiji distribution of ImageJ 27 . Integrated densities for bands of the same protein species were measured using a consistently sized rectangle, and background measurements from the same lane were subtracted from these values. We normalized proteinof-interest bands by dividing by loading control bands, which were quantified via the same method. Data analysis was done in Excel (Microsoft) and OpenOffice (Apache) software.
Microscopy. Brightfield microscopy of live StaPLd-Casp9-expressing HeLa cells (in 12-well plates; Greiner Bio-One) was performed on an EVOS FL Cell Imaging System with a 4× /0.1-numerical aperture (NA) air objective. Fluorescence widefield microscopy of live transfected HeLa cells (in 35-mm glass-bottom fourchamber dishes; In Vitro Scientific), live or fixed transfected HEK293-TRE3G-mCherry stable cells (in plastic 12-well plates (Greiner Bio-One) or glass-bottom 12-well plates (In Vitro Scientific)), and stained/fixed StaPLd-Casp9-expressing HeLa cells (mounted on glass slides with #1.5 coverslips) was performed on an Axiovert 200 M inverted microscope (Zeiss) with 40× /1.2-NA water-immersion, 5× /0.25-NA air, and 10× /0.5-NA air objectives, respectively. The following excitation (ex) and emission (em) filters were used: Green/Yellow (YFP, Alexa Fluor 488), ex 485/10 nm (Chroma), em 510 nm long-pass dichroic (Omega) and 525/40 nm (Chroma); Red (RFP, eqRFP), ex 568/20 nm (Omega), em 585 longpass dichroic (Chroma) and 620/60 nm (Chroma). Excitation was from an X-Cite 120-W metal-halide lamp with a 3-mm-core liquid light guide (Lumen Dynamics), and acquisition was performed by an ORCA-ER camera (Hamamatsu). The system was controlled by a MacBook Pro computer (A1261; Apple) running the MacOS 10.6.8 operating system (Apple) and Micro-Manager 1.4.10 software 28 .
Confocal fluorescence microscopy of live transfected HEK293A cells was done in 35-mm glass-bottom four-chamber dishes (In Vitro Scientific) on an UltraVIEW VoX system (PerkinElmer) equipped with a CSU-X1 spinning disc (Yokogawa Electric) and a C9100-50 EM-CCD (electron-multiplying charge-coupled device) camera (Hamamatsu), controlled by Volocity 5 software (Improvision). Imaging was done with an Apochromat 63× /1.4-NA oil-immersion objective (Zeiss). The following ex lasers (at 30% power) and em filters were used: YFP, ex 488 nm laser, em 525/50 nm; RFP, ex 561 nm laser, em 615/70 nm.
Plastic 12-well plates or glass-bottom cell-culture vessels for HEK293/ HEK293A cells were typically coated with 0.5 mg/ml poly-d-lysine hydrobromide (Sigma-Aldrich) in water by incubation at 37 °C for 4 h to overnight, and were washed four times with water before cells were plated. Live StaPLd-Casp9 HeLa cells were imaged in DMEM supplemented as described above, and live transfected HeLa cells and HEK293-TRE3G-mCherry cells were imaged in Hank's Balanced Salt Solution (HBSS; Hyclone). In the case of time course experiments, appropriate protease inhibitor drug was maintained in HBSS during imaging before cells were returned to fresh drug-containing DMEM. Live transfected HEK293A cells were imaged in FluoroBrite DMEM (Life Technologies) supplemented as described above. Fixed cells were fixed with 4% paraformaldehyde (Electron Microscopy Sciences) in phospho-buffered saline (PBS; HyClone) for 15 min at ambient temperature, washed twice with HBSS, and subsequently stored in HBSS.
Image processing and analysis were done with Fiji. For stained/fixed StaPLd-Casp9-expressing HeLa cells, 10-µ m-tall z-stacks were acquired in 1-µ m intervals and were subsequently transformed into maximum-intensity projections and background-subtracted. For live transfected HEK293A cells, z-stacks were acquired in 0.5-µ m intervals and ranges encompassing 4 µ m were transformed into maximum-intensity projections. For live or fixed transfected HEK293-TRE3G-mCherry cells, background-subtracted images were quantified for RFP fluorescence using the integrated density function.
Enzyme-linked immunosorbent assay. HEK293A cells were cultured in 12well plates (Greiner Bio-One) with 1 ml of DMEM (supplemented as previously described) in each well and were transfected 48 h before harvesting of media supernatants (transfection reagent volume: 200 µ l). Media were not changed after transfection. Appropriate protease-inhibitor drugs were applied concurrently with transfection. Cells transfected with empty vector and given identical protease-inhibitor treatments served as controls. From each well, 900 µ l of media supernatant was collected for ELISA analysis and frozen at -20 °C until it was processed. Samples were thawed to ambient temperature 1 h before use, and were cleared by centrifuging at 10,000g for 10 min at 4 °C.
We carried out sandwich ELISA with the Human VEGF Quantikine ELISA kit (R&D Systems) according to the manufacturer's protocol. Absorbances at 450 nm (with reference wavelength 540 nm) were measured thrice and averaged, using an Infinite M1000 PRO plate reader (Tecan) under the control of i-control software (Tecan). Human VEGF protein dilution standards were used to calculate sample [VEGF] values by four-parameter logistic regression (http://www.elisaanalysis. com). In some cases, sample measurements exceeded those of the top standard value, and were diluted twofold and rescanned for interpolation. The calculated [VEGF] for such samples was thus multiplied by two. Because each well of HEK293A contained 1.2 ml of media post-transfection, [VEGF] values were adjusted by a factor of 1.2 to obtain true concentrations in picograms per milliliter. VEGF measurements are expressed as differences from cells transfected with empty vector and incubated in similar drug conditions. Quantitative real-time PCR. To measure mRNA levels in HEK293A or HEK293-TRE3G-mCherry cells, we first plated cells on plastic 12-well plates (Greiner Bio-One or Thermo Scientific Nunclon Delta Surface). For HEK293-TRE3G-mCherry cells, plates were coated with 0.5 mg/ml poly-d-lysine hydrobromide (Sigma-Aldrich) in water by incubation at 37 °C for 4 h to overnight, and were washed four times with water before plating. We harvested cells by aspirating media and lysing with 500 µ l of RNA lysis buffer (Zymo). Lysates were frozen at -20 °C before processing of 150 µ l of each sample with molecular-biology-grade ethanol (Sigma) and the Quick-RNA Microprep kit (Zymo), which incorporates a DNase digestion step. Extracted RNAs were verified as having 260/230 and 260/280 ratios of > 1.8 by a NanoDrop spectrophotometer (Thermo Fisher); otherwise they were re-extracted.
RNAs were reverse-transcribed with Superscript IV VILO Master Mix (Thermo Fisher) according to the manufacturer's instructions. Prior to reverse transcription, concentrations of RNA samples were normalized by dilution of some samples with RNase-free water. Each RNA sample was reverse-transcribed in duplicate. cDNAs were used as templates in PCR reactions using the Applied Biosystems Taqman Gene Expression Master Mix (Fisher Scientific). PCR reactions (10 µ l) were performed in Hard-Shell thin-wall 384-well PCR plates (Bio-Rad) sealed with Microseal B adhesive (Bio-Rad) and were analyzed on a Bio-Rad CFX384 thermocycler. Each PCR reaction for a given cDNA sample was performed in duplicate. All steps were performed using barrier pipette tips.
PCR primers and Taqman probes were synthesized by Integrated DNA Technologies and used at final concentrations of 500 nM for primers and 250 nM for probes. Sequences of primer pairs and probes were as follows:
mCherry RFP forward primer, GAGGCTGAAGCTGAAGGAC mCherry RFP reverse primer, GATGGTGTAGTCCTCGTTGTG mCherry RFP probe, 56-FAM/CCAACTTGA/ZEN/ TGTTGACGTTGTAGGCG/3IABkFQ Human VEGFA forward primer, CCATGAACTTTCTGCTGTCTTG Human VEGFA reverse primer (exon-spanning), TGAACTTCACCACTTCGTGAT Human VEGFA probe, 56-FAM/TGCTCTACC/ZEN/ TCCACCATGCCAAG/3IABkFQ Human GAPDH forward primer, CCATGTTCGTCATGGGTGTGA Human GAPDH forward primer (exon-spanning), CATGGACTGTGGTCATGAGT Human GAPDH probe, 56-FAM/TCCTGCACC/ZEN/ ACCAACTGCTTAGCA/3IABkFQ.
Using dilution series, we verified that primer/probe sets had efficiencies of > 90%, and that pairs of primer/probe sets (RFP and GAPDH, VEGFA and GAPDH) had efficiencies within 5% of one another. We calculated Cq values from amplification curves using the Single Threshold method in CFX Manager software (Bio-Rad). Data were analyzed in Excel. We obtained relative gene expression values by the ddCq method: first, Cq values for genes of interest were normalized by the housekeeping gene GAPDH, and then the resultant values were normalized to drug-and/or time-matched empty-vectortransfected controls.
Cell staining. To assess the activity of engineered suicide genes, we stained StaPLd-Casp9-expressing or iCasp9-expressing HeLa cells after drug incubation. Media were collected to harvest dead/lifted cells, adherent cells were trypsinized to harvest living cells, and the two were pooled and pelleted at 500g for 5 min. Cells were washed once with HBSS, resuspended in either HBSS or annexin V binding buffer (Biotium), and stained with the NucView 488 caspase-3 assay kit for live cells (Biotium) or the annexin V CF488A conjugate kit (Biotium), respectively, according to the manufacturer's instructions. In some instances, cells of the parent cell line (Flp-In HeLa) were annexin-V-stained in parallel. For medium-term preservation, cells were fixed in 4% PFA in PBS for 15 min at ambient temperature after staining, centrifuged at 10,000g, and resuspended in HBSS after aspiration of the PFA. For microscopy, a 25-µ l droplet of each sample was then placed on a Superfrost Plus glass slide (Fisher Scientific) and allowed to dry partially before the addition of Vectashield mounting medium with DAPI (Vector Labs) and a #1.5 coverslip (Fisher Scientific). Slides were sealed with clear nail polish and kept at 4 °C.
Flow cytometry. Flow cytometry was performed on live or fixed cells (for annexin-V-stained cells) or fixed cells (for the caspase-3 sensor) prepared as described above, using a Digital Vantage instrument (Becton Dickinson) under the control of CellQuest software (Becton Dickinson), operated by the Stanford Shared FACS Facility. A 488-nm laser was used to excite Alexa Fluor 488 stain, and a 594-nm laser was used to excite eqRFP. The parent Flp-In HeLa cell line, which did not express eqRFP, was used to confirm eqRFP-positive monoclonal populations for the stable cell lines. For each sample, 10 4 events were collected. Gates were constructed inside forward scatter and side scatter plots (FSC-A versus SSC-A and FSC-H versus FSC-A) to exclude debris and non-singlet events, respectively ( Supplementary Fig. 11c ). Cytometry data were analyzed and processed with FlowJo software (FlowJo LLC).
Statistical analyses.
Statistical analyses were carried out with Excel (Microsoft) and Prism (Graphpad). To test for significant pairwise differences between drug responsiveness of SMASh WT , SMASh AI , and SMASh TI variants for a given ASV or TPV drug concentration, normality of the data were confirmed by the Shapiro-Wilk normality test, then data were subjected to two-way ANOVA, with multiple comparisons between each variant's mean normalized NS3 activity for each concentration of ASV and TPV. Data for ASV and TPV were analyzed separately. P values from multiple comparisons were corrected post hoc by Tukey test.
Corrected P values are as follows: 0.01 µ M ASV: NS3 wt versus NS3 AI , P = 0.2476; NS3 wt versus NS3 TI , P = 0.9568; NS3 AI versus NS3 TI , P = 0.1530 0.1 µ M ASV: NS3 wt versus NS3 AI , P = 0.1404; NS3 wt versus NS3 TI , P = 0.0017; NS3 AI versus NS3 TI , P = < 0.0001 1 µ M ASV: NS3 wt versus NS3 AI , P = > 0.9999; NS3 wt versus NS3 TI , P = < 0.0001; NS3 AI versus NS3 TI , P = < 0.0001 10 µ M ASV: NS3 wt versus NS3 AI , P = 0.9063; NS3 wt versus NS3 TI , P = 0.0001; NS3 AI versus NS3 TI , P = < 0.0001 0.1 µ M TPV: NS3 wt versus NS3 AI , P = 0.9174; NS3 wt versus NS3 TI , P = 0.2797; NS3 AI versus NS3 TI , P = 0.4779 1 µ M TPV: NS3 wt versus NS3 AI , P = 0.3484; NS3 wt versus NS3 TI , P = 0.0088; NS3 AI versus NS3 TI , P = 0.1513 10 µ M TPV: NS3 wt versus NS3 AI , P = 0.2116; NS3 wt versus NS3 TI , P = 0.0088; NS3 AI versus NS3 TI , P = 0.0002
To test for significant pairwise differences between VEGF secretion in different drug conditions for the given zinc-finger construct or constructs, we confirmed normality of the data by the Shapiro-Wilk normality test, then subjected the data to one-way ANOVA, with multiple comparisons between mean normalized VEGF concentration for each drug condition. Data for each expressed zinc-finger construct were analyzed separately. P values from multiple comparisons were corrected post hoc by Tukey test. Corrected P values are as follows:
1 nature research | reporting summary A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Sample size
Sample/replicate sizes were selected to comport with current standards in the field. For key experiments this meant attaining n=3 or more.
Data exclusions In one independent VEGF ELISA experiment (For Figure 1d ), the measured [VEGF] for empty vector-transfected, TPV-treated cells was over 3
times higher than that of empty vector-transfected cells treated with ASV or DMSO. Since drug-matched empty vector control wells were used to normalize data, the anomalous empty vector value made data difficult to confidently interpret, and so these data were excluded from analysis.
In the immunoblot experiment used to compare NS3 mutant variants ( Supplementary Figure 1b -c, Supplementary Figure 2a) , several of the 8sample series were difficult to quantify due to handling artefacts (creasing, smudging, uneven staining) and were thus excluded from analysis. Retained lysates were used to perform reruns of SDS-PAGE and immunoblotting and generate usable data for quantification.
In several microscopy and RT-qPCR experiments used to assess the performance of VPR-dCas9(StaPLTI) (Figure 2b -c, Supplementary Figure  9b ,d,f), TPV induction of RFP fluorescence or mRNA was found to be suboptimal. This was found to be attributable to poor transfection efficiency due to cell culture conditions and transfection method, and these data were excluded. Using a different serum source, using plastic growth substrates instead of glass, and using Cal Phos instead of Lipofectamine improved transfection efficiency and reproducibility of findings.
In several RT-qPCR experiments used to assess the performance of ZFVEGFA-StaPLAI-YFP-VPR ( Supplementary Figure 9c ,e,g), ASV induction of VEGFA mRNA was found to be suboptimal. This was attributed to poor transfection efficiency due to cell culture conditions, and these data were excluded. Using a different serum source and high-purity plasmids for transfection improved transfection efficiency and reproducibility of findings.
In initial flow cytometry experiments used to query the dosage-dependence and timecourse of apoptosis due to StaPLd-Casp9, and to compare StaPLd-Casp9 to iCasp9 ( Supplementary Figures 12, 13, 14) , the peak StaPLd-Casp9-triggered apoptosis in 1 μM ASV was found to be suboptimal, which was likely attributable to using an older passage of the stable cell line. Earlier data were excluded in favor of data obtained from younger passage cells.
Replication
For key findings, at least 3 independent experiments were performed in order to gauge the reproducibility of results. In some cases, findings were corroborated through the use of different assays to generate converging lines of evidence (e.g. by immunoblot and fluorescence microscopy, or by fluorescence microscopy and RT-qPCR). As the outcome of cell culture experiments was highly contingent upon expression of protein constructs, reproducibility was ensured by using low-passage cells, high-quality serum, high-purity plasmids (if applicable), and optimizing growth substrate and transfection method (if applicable).
Randomization No randomization was performed, as the study did not involve discrete human or animal subjects.
Blinding
Experimenters were not blinded, as most datasets were gathered in an automatic fashion by machines (plate spectrophotometer, real-time thermocycler).
Reporting for specific materials, systems and methods
Validation -Mouse anti-PSD95 has been used extensively in our lab for western blotting. Diminished intensity or absence of a PSD95 immunopositive band in conditions where PSD95 is expected to be degraded by SMASh serve as validation ( Supplementary  Figure 1a-b, Figure 1c ).
-Rabbit anti-β-actin has been used extensively in our lab for western blotting. The manufacturer has validated the antibody, noting decreased intensity of the β-actin immunopositive band in cells transfected with shRNA against β-actin.
-Rabbit anti-GAPDH has been used extensively in our lab for western blotting. The manufacturer has validated the antibody by testing it against a GAPDH transfected 293T cell control lysate (sc-159909).
-Rabbit anti-Arc has been used extensively in our lab for western blotting. Absence of an Arc immunopositive band in conditions where Arc is expected to be degraded by SMASh serve as validation (Figure 1c ).
-Mouse anti-GFP has been used extensively in our lab for western blotting against YFP. The manufacturer has verified it does not produce a band in untransfected cell lysates. We independently validate the antibody by demonstrating it does not produce a band for cells that were not transfected with a YFP-containing construct ( Supplementary Figure 3 ).
-Rabbit anti-tdTomato was verified by the manufacturer not to produce a western blot band in untransfected cell lysates. We independently validate the antibody by demonstrating it does not produce a band for cells that were not transfected with an RFP-containing construct ( Supplementary Figure 3 ).
-Rabbit anti-HA has been used extensively in our lab for western blotting against the HA epitope. To validate the antibody, the manufacturer has verified that no band is produced in untransfected cell lysates.
-Mouse anti-GAPDH has been used extensively in our lab for western blotting, and has been cited extensively in the literature.
-Mouse anti-HA was validated by the manufacturer, who demonstrated that a western blot band is not produced for cells that do not express an HA-tagged protein.
-Rabbit anti-eqRFP was verified by the manufacturer not to produce a western blot band in cells transfected with fluorescent proteins belonging to other families.
-Mouse anti-β-actin has been used extensively in our lab for western blotting. The manufacturer validated the antibody by demonstrating that the intensity of a β-actin immunopositive band is strengthened in lysates of cells transfected with β-actin.
-The LI-COR secondary antibodies have been used extensively in our lab for western blotting, are designed to have minimal cross-reactivity, and are extensively cited in the literature. Authentication Cell lines were not stringently authenticated, but visual inspections of cells comported with expected morphologies.
Eukaryotic cell lines
Mycoplasma contamination
Cell lines were not tested for mycoplasma.
Commonly misidentified lines (See ICLAC register) HEK293 cell lines were used in this study. HEK are listed in Version 8 of the ICLAC database of commonly misidentified or cross-contaminated lines, with HeLa listed as the contaminating cell line. Despite the risk for misidentification/contamination, we deem the use of HEK293 cells to be justifiable since this cell line has been typically utilized for the types of experiments we needed to perform (VEGF ELISA, dCas9 transfection and RT-qPCR). Further, we deem the risk of misidentification to be low. The morphologies of HEK and HeLa are visually discriminable and cell lines were regularly visually inspected (2-3 times per week).
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology Sample preparation
StaPLd-Casp9-expressing or iCasp9-expressing HeLa cells were stained after drug incubation. Media were collected to harvest dead/lifted cells, adherent cells were trypsinized to harvest living cells, and the two were pooled and pelleted at 500g for 5 min. Cells were washed once with HBSS, resuspended in either HBSS or Annexin V Binding Buffer (Biotium), and stained with the NucView 488 Caspase-3 Assay Kit for Live Cells (Biotium) or the Annexin V CF488A Conjugate kit (Biotium), respectively, according to manufacturer's instructions. In some instances, cells of the parent cell line (Flp-In HeLa) were annexin V-stained in parallel. For medium-term preservation, cells were fixed in 4% PFA in PBS for 15 min at ambient temperature following staining, centrifuged at 10,000g, and resuspended in HBSS after aspirating the PFA. Cell population abundance Flow cytometry data was collected but no sorting was performed For each sample, 10,000 events were collected.
Instrument
Gating strategy
Gates were constructed inside forward scatter and side scatter plots (SSC-A vs. FSC-A and FSC-A vs. FSC-H) to exclude debris and non-singlet events, respectively. (See Supplementary Figure 11c ).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
